Sermorelin has no FDA prescribing label of its own. The brand that once carried it, Geref, was discontinued years ago. Everything sold today is compounded — made to order by a pharmacy rather than manufactured under an approved application. See sermorelin’s FDA status in full for how that came about. That single fact changes how the “who shouldn’t take this” question has to be answered. There is no official contraindications section to quote. What exists instead is a mechanistic picture, a closely related drug’s label, and a prescriber’s own screening judgment.
This is a description of that picture, not an instruction. Nothing here tells you to take, avoid, or stop anything. It lays out what labels and regulators actually say, what a prescriber typically checks, and where the evidence runs out entirely.
Why sermorelin has no label of its own
Two versions of Geref were once FDA-approved: a 1990 injectable ampule, and a 1997 injectable vial, both from EMD Serono. Both are listed in the FDA’s own drug application database as discontinued. Both carry the same regulatory note in that record: “Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons” [1]. That is a specific, favorable regulatory fact. It is also an old one, for a product that no longer exists on a pharmacy shelf.
What is sold today is sermorelin acetate as bulk compounding powder. A compounding pharmacy reconstitutes it under state and federal rules for compounded drugs — see how a compounding pharmacy documents that. It is not dispensed as an FDA-approved finished product. A compounded drug does not come with its own FDA-reviewed prescribing information. There is no Contraindications section to cite, because the regulatory process that produces one never ran for sermorelin as it is sold now.
What the label for the closest approved relative says
Tesamorelin is a different molecule in the same drug class. It is a growth hormone-releasing hormone analog, and it works the same way sermorelin does — prompting the pituitary to release the body’s own growth hormone; see the full sermorelin vs. tesamorelin comparison. Unlike sermorelin, tesamorelin is currently FDA-approved, sold under the brand Egrifta, with an active label on file. That label states, verbatim, where the drug is contraindicated:
“Patients with disruption of the hypothalamic-pituitary axis due to hypophysectomy, hypopituitarism, pituitary tumor/surgery, head irradiation or head trauma. Patients with active malignancy. Any preexisting malignancy should be inactive and its treatment complete prior to instituting therapy. Patients with known hypersensitivity to tesamorelin or the excipients. Pregnant women.” [2]
This is tesamorelin’s label, not sermorelin’s. No equivalent document exists for sermorelin itself. But the mechanism is shared, and the reasoning behind each line applies to any drug in this class that works the same way.
Active malignancy: the mechanistic reasoning
Tesamorelin’s label explains the malignancy line directly. The drug “induces the release of endogenous growth hormone (GH), a known growth factor,” and prescribers are instructed not to treat active malignancy with it [2]. Growth hormone and its downstream signal, IGF-1, promote cell growth generally. That is not unique to cancer cells, but it is exactly the property a prescriber would want to avoid amplifying in someone with an active tumor.
No human clinical or epidemiological study has linked sermorelin therapy to increased cancer risk, across 116 PubMed records searched under cancer, tumor, neoplasm and malignancy terms [4]. One preclinical study is worth naming here. It found that native GHRH — not sermorelin, and not at a clinical dose — increased proliferation in non-cancerous prostate cells in a lab dish, and the same treated cells produced tumors when injected into mice [3]. That is laboratory evidence for a plausible mechanism, not evidence of harm in a person taking sermorelin. It is also exactly the kind of signal that explains why active malignancy sits as a hard contraindication on the closest approved relative’s label, and a reasonable basis for an intake screen to ask about it too.
Pregnancy: the honest gap
Tesamorelin’s label is unambiguous on pregnancy, and unusually specific about why. Pregnant rats given tesamorelin at roughly two to four times the human clinical exposure had offspring with hydrocephaly; lower doses caused delayed skull ossification. Rabbits, by contrast, showed no adverse developmental effects, even at doses around 500 times the clinical exposure [2]. That is a reminder that animal-species results do not always agree with each other, let alone predict a human outcome.
Sermorelin has no equivalent data published anywhere. A search of everything PubMed has indexed connecting sermorelin to pregnancy returns 9 records. None is a human safety study — they are animal lactation-physiology papers, in dairy cattle, sows, and rats, plus laboratory studies of placental cell biology [4]. None involves a pregnant patient taking the drug. There is no sermorelin-specific pregnancy safety data in either direction — not evidence of risk, and not evidence of safety.
The hypothalamic-pituitary axis: a mechanical requirement, not just a screening item
The first line of tesamorelin’s contraindication list is not about malignancy at all. It rules out prior pituitary surgery, hypopituitarism, a pituitary tumor, or head irradiation or trauma affecting that axis [2]. This one is less a safety concern than a mechanical fact. Sermorelin, like tesamorelin, works only by asking an intact pituitary to release growth hormone it can still produce — see how that mechanism plays out in the one adult trial. If that gland’s ability to respond is already disrupted, the entire mechanism the drug depends on is compromised before the first dose.
What a prescriber's intake screen typically covers
Consistent with the reasoning above, an intake for a compounded GHRH analog commonly asks about several things: current or recent cancer treatment; personal and family cancer history; pregnancy or breastfeeding status; known pituitary conditions or pituitary surgery; and hypersensitivity to peptide medications. See the fuller list of questions an intake typically covers. This describes how that screening generally works. It is not a substitute for one, and not a recommendation about any individual situation.
Where the evidence simply runs out
The one adult trial that exists tested sermorelin in people aged 55 to 71. Nobody has published a trial in adults outside that narrow band. Pediatric sermorelin trials studied a different population, for a different purpose — growth hormone deficiency in children, at different doses than what is marketed to adults today. No trial has followed sermorelin users for more than about a year. No long-term human safety surveillance exists for this drug at all. A description of who shouldn’t take sermorelin is, in the end, partly a description of how much has never been studied.